Clinical Trial Update: Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302） [Phase 2]

View source ↗

Summary

Phase II trial of Anlotinib in patients with advanced non-small cell lung cancer (ALTER0302) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED